Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trigger Point Injection in Reducing Pain Following Total Knee Arthroplasty
NCT06955923Phase 2Completed
- Sponsor
- David Grant USAF Medical Center
- Start
- May 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of lidocaine in myofascial pain syndrome (MPS) (2 arms), sponsored by David Grant USAF Medical Center. Primary endpoint: Pain Scores on the Visual Analog Scale at 6 weeks. Started May 2025; status: completed.
02
Drugs
lidocaine
03
Conditions
myofascial pain syndrome (MPS)
Beyond the preview
Go deeper on NCT06955923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06955923.